Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)

Trial Profile

Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Afatinib (Primary) ; Dasatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top